- Home
- FENC vs ACIU Comparison
FENC vs ACIU Comparison
Compare FENC & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | ACIU |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 266.4M | 213.3M |
| IPO Year | 2010 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FENC | ACIU |
|---|---|---|
| Price | $5.86 | $3.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $15.00 | $10.00 |
| AVG Volume (30 Days) | 206.5K | ★ 244.5K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $44,642,000.00 | N/A |
| Revenue This Year | $69.68 | $635.38 |
| Revenue Next Year | $37.30 | $232.58 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.98 | $1.45 |
| 52 Week High | $9.92 | $4.00 |
Technical Indicators
Market Signals| Indicator | FENC | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 34.75 | 61.19 |
| Support Level | $5.65 | $3.18 |
| Resistance Level | $9.16 | $3.43 |
| Average True Range (ATR) | 0.44 | 0.20 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 10.70 | 81.91 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.